Dr. Defilipp is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street
Boston, MA 02114Phone+1 617-724-3456Fax+1 617-643-5843
Summary
- Dr. Zachariah Defilipp is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Tel Aviv University Sackler and has been in practice 7 years. He specializes in hematologic oncology and is experienced in bone marrow transplantation, stem cell transplantation, and leukemia. He has more than 100 publications and over 500 citings.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2013 - 2016
Allegheny Health Network Medical Education Consortium (AGH)Residency, Internal Medicine, 2010 - 2013
Tel Aviv University SacklerClass of 2010
Certifications & Licensure
MA State Medical License 2016 - 2026
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
PA State Medical License 2010 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2019 Apr 19
- Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2019 Jan 15
Publications & Presentations
PubMed
- A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.Zachariah DeFilipp, Haesook T Kim, Guang-Shing Cheng, Betty K Hamilton, Saurabh Chhabra
Blood Advances. 2025-01-28 - Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk
Transplantation and Cellular Therapy. 2025-01-01 - Factors Associated With Increased Risk of Contamination in Bone Marrow Transplants.Eashwar Somasundaram, Rachel Gill, Nicole Hartford, Kerry Collier, Steven M McAfee
Transplantation and Cellular Therapy. 2025-01-01
Journal Articles
- Indoles Derived from Intestinal Microbiota Act via Type I Interferon Signaling to Limit Graft-Versus-Host-DiseaseEdmund K Waller, Zachariah DeFilipp, Muna Qayed, Akshay Sharma, Blood
Abstracts/Posters
- The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host DiseaseZachariah Defilipp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic DiseasesZachariah Defilipp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T CellsZachariah Defilipp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Horror Stories Underscore FMT RisksOctober 30th, 2019
Sepsis Linked to Fecal Microbiota TransplantationOctober 30th, 2019- A Sepsis Death Linked to Fecal Microbiota TransplantationOctober 30th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
